Eyenovia
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 57
- Market Cap
- $43.8M
- Website
- http://www.eyenovia.com
- Introduction
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
- Conditions
- Mydriasis
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06217796
- Locations
- 🇺🇸
SUNY, New York, New York, United States
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
- Conditions
- Presbyopia
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT05114486
- Locations
- 🇺🇸
VISION-2 Study Site #57, San Diego, California, United States
🇺🇸VISION-2 Study Site #59, Fairfield, Connecticut, United States
🇺🇸VISION-2 Study Site #56, Louisville, Kentucky, United States
Evaluation of Pupil Dilation Speed With the MAP Dispenser
- Conditions
- Mydriasis
- Interventions
- Drug: tropicamide-phenylephrine fixed combination ophthalmic solution
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04907474
- Locations
- 🇲🇽
CODET Vision Institute, Tijuana, Baja California, Mexico
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT04657172
- Locations
- 🇺🇸
VISION-1 Study Site #21, Azusa, California, United States
🇺🇸VISION-1 Study Site #52, Newport Beach, California, United States
🇺🇸VISION-1 Study Site #54, Fort Collins, Colorado, United States
Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
- Conditions
- Myopia
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Eyenovia Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT03942419
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Optometry, Birmingham, Alabama, United States
🇺🇸Midwestern University, Downers Grove, Illinois, United States
🇺🇸Canyon City Eyecare, Azusa, California, United States
- Prev
- 1
- 2
- Next
News
Formosa Pharmaceuticals and Cipla Form Strategic Partnership for APP13007 Commercialization Across 11 Countries
Formosa Pharmaceuticals has granted Cipla Limited exclusive rights to market clobetasol propionate ophthalmic suspension 0.05% (APP13007) across 11 countries in Asia, Africa, and South America.
Eyenovia and Betaliq Plan Reverse Merger to Create Innovative Ophthalmic Technology Company
Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity.
Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis
• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.
Eyenovia's Stock Plummets After Phase III Myopia Trial Fails to Meet Primary Endpoint
Eyenovia's stock price plummeted after its Phase III CHAPERONE study, evaluating a drug-device combination for pediatric progressive myopia, failed to meet its primary endpoint.
Eyenovia's Myopia Trial Fails, Stock Plummets
Eyenovia's stock price plummeted after its Phase III CHAPERONE study for pediatric progressive myopia failed to meet the primary endpoint.
Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint in Pediatric Myopia
Eyenovia's Phase 3 CHAPERONE study, evaluating low-dose atropine via Optejet for pediatric myopia, did not meet its primary endpoint of less than 0.5 diopter progression over three years.
Eyenovia Halts Phase III Myopia Trial, Explores Strategic Alternatives
Eyenovia discontinues its Phase III clinical trial for a drug-device combination product aimed at treating pediatric myopia after an unfavorable assessment by the data monitoring committee.
Eyenovia's Stock Plummets After Phase III Myopia Study Fails
Eyenovia discontinued its Phase III CHAPERONE study for MicroPine, a low-dose atropine treatment for pediatric progressive myopia, after it failed to meet the primary endpoint.
Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint in Pediatric Myopia
Eyenovia's Phase 3 CHAPERONE study, evaluating low-dose atropine for pediatric progressive myopia, did not meet its primary endpoint.
Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint for Pediatric Myopia
Eyenovia's CHAPERONE Phase 3 trial, evaluating low-dose atropine via Optejet for pediatric myopia, did not meet its primary endpoint of slowing myopia progression over three years.